Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples